These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20524709)

  • 1. Long-term pharmacotherapy for obesity in elderly patients: a retrospective evaluation of medical records from a specialized obesity outpatient clinic.
    Horie NC; Cercato C; Mancini MC; Halpern A
    Drugs Aging; 2010 Jun; 27(6):497-506. PubMed ID: 20524709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy for obesity.
    Ioannides-Demos LL; Proietto J; McNeil JJ
    Drugs; 2005; 65(10):1391-418. PubMed ID: 15977970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug interventions for the treatment of obesity in children and adolescents.
    Mead E; Atkinson G; Richter B; Metzendorf MI; Baur L; Finer N; Corpeleijn E; O'Malley C; Ells LJ
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012436. PubMed ID: 27899001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
    Norris SL; Zhang X; Avenell A; Gregg E; Schmid CH; Lau J
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD004096. PubMed ID: 15674929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis: pharmacologic treatment of obesity.
    Li Z; Maglione M; Tu W; Mojica W; Arterburn D; Shugarman LR; Hilton L; Suttorp M; Solomon V; Shekelle PG; Morton SC
    Ann Intern Med; 2005 Apr; 142(7):532-46. PubMed ID: 15809465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
    Suplicy H; Boguszewski CL; dos Santos CM; do Desterro de Figueiredo M; Cunha DR; Radominski R
    Int J Obes (Lond); 2014 Aug; 38(8):1097-103. PubMed ID: 24287940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination phentermine and topiramate for weight maintenance: the first Australian experience.
    Neoh SL; Sumithran P; Haywood CJ; Houlihan CA; Lee FT; Proietto J
    Med J Aust; 2014 Aug; 201(4):224-6. PubMed ID: 25164851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
    Leung WY; Thomas GN; Chan JC; Tomlinson B
    Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabesity: are weight loss medications effective?
    Halpern A; Mancini MC
    Treat Endocrinol; 2005; 4(2):65-74. PubMed ID: 15783244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
    Erondu N; Addy C; Lu K; Mallick M; Musser B; Gantz I; Proietto J; Astrup A; Toubro S; Rissannen AM; Tonstad S; Haynes WG; Gottesdiener KM; Kaufman KD; Amatruda JM; Heymsfield SB
    Obesity (Silver Spring); 2007 Aug; 15(8):2027-42. PubMed ID: 17712121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of drug therapies used for weight loss and treatment of obesity.
    Ioannides-Demos LL; Proietto J; Tonkin AM; McNeil JJ
    Drug Saf; 2006; 29(4):277-302. PubMed ID: 16569079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.
    Gursoy A; Erdogan MF; Cin MO; Cesur M; Baskal N
    Eat Weight Disord; 2006 Dec; 11(4):e127-32. PubMed ID: 17272944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.
    Sari R; Balci MK; Cakir M; Altunbas H; Karayalcin U
    Endocr Res; 2004 May; 30(2):159-67. PubMed ID: 15473126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals.
    Hemo B; Endevelt R; Porath A; Stampfer MJ; Shai I
    Diabetes Res Clin Pract; 2011 Nov; 94(2):269-75. PubMed ID: 21907442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.